Please assess the completion status of the following clinical trial:

Trial Title: MEmbranous Nephropathy Trial Of Rituximab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Idiopathic MN with diagnostic biopsy~* Female, must be post-menopausal, surgically sterile or practicing a medically approved method of contraception(no birth-control pill)~* Must be off prednisone or mycophenolate mofetil for \>1 month and alkylating agents for \>6 months.~* angiotensin-converting-enzyme inhibitor (ACEi) and/or Angiotensin II receptor blockers (ARB), for \>3 months prior to randomization and adequate blood pressure (target BP \<130/80 millimeter of mercury (mmHg) in \>75% of the readings, but subjects with BP \<140/80 mmHg in \>75% of the readings will be eligible). Patients with documented evidence of \>3 months treatment with maximal angiotensin II blockade, on an 3-hydroxy-3-methylglutaryl-CoA lyase (HMG-CoA) reductase inhibitor, and BP control (BP \<140/80 mmHg in \>75% of the readings) who remain with proteinuria \>5g/24h may enter and be randomized to RTX/CSA without the need of the run-in/conservative phase of the study.~* Proteinuria \>5g/24h on two 24-hour urine collection collected within 14 days of each other~* Estimated glomerular filtration rate (GFR) ≥40 ml/min/1.73m2 while taking ACEi/ARB therapy OR quantified endogenous creatinine clearance \>40 ml/min/1.73m2 based on a 24-hour urine collection.~Exclusion Criteria~* Presence of active infection or a secondary cause of MN (e.g. hepatitis B, systemic lupus erythematosus (SLE), medications, malignancies). Testing for HIV, Hepatitis B and C should have occurred \<2 years prior to enrollment into the study.~* Type 1 or 2 diabetes mellitus: to exclude proteinuria secondary to diabetic nephropathy. Patients who have recent history of steroid induced diabetes but no evidence on renal biopsy performed within 6 months of entry into the study are eligible for enrollment.~* Pregnancy or breast feeding for safety reasons~* History of resistance to CSA (or other calcineurin inhibitors, e.g. tacrolimus), RTX or alkylating agents (e.g. Cytoxan). Patients who previously responded to CSA/Calcineurin Inhibitor (CNI), RTX or alkylating agents with either a complete remission (CR) or partial remission (PR) but relapsed off CSA/CNI after 3 months or relapsed off RTX or alkylating agent after 6 months are eligible.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Rituximab Treatment Arm (Type: ACTIVE_COMPARATOR): Patients randomized to the RTX arm will receive 1000 mg IV on Days 1 and 15. Patients who achieve complete remission at 6 months will not be retreated. A second course of RTX 1000 mg IV will be administered at study month 6 for individuals who have not achieved a complete remission, but have achieved a minimum of \>25% reduction in Time 0 proteinuria. Dosing at study month 6 will be independent of cluster of differentiation (CD) 19+ B cell count.
- Cyclosporine Treatment Arm (Type: ACTIVE_COMPARATOR): Patients randomized to the Cyclosporine arm will be started at a dose of CsA = 3.5 mg/kg/day p.o. divided into 2 equal doses given at 12 hour intervals. Target trough CsA blood levels are 125 to 175 ng/ml. Patients will have their doses adjusted according to their blood levels of CSA as monitored every 2 weeks until the target trough level is reached. If a complete remission is achieved by 6 months, CSA will be tapered and discontinued over a three-month period. If after 6 months there has not been a reduction in proteinuria of at least 25% of baseline values, the drug will also be discontinued. If there has been a \>25% reduction in baseline proteinuria (but not complete remission) the CSA will be continued for an additional 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).